Latest in Finance

ITT to acquire SPX FLOW in $4.8bn deal, expanding global leadership in engineered components and flow technologies

Acquisition strengthens ITT’s position in industrial, chemical, energy, health and nutrition markets, adding high-margin revenue, major aftermarket growth and $80m in expected synergies by year three

Find out more

Grace and Molecule.One join forces to transform peptide building block synthesis with AI

The pair have entered into a multi-year strategic agreement to accelerate drug development timelines, strengthen US manufacturing capabilities and help bring lifesaving...
See more

Thermo Fisher Scientific doubles down on investment in Asia

New and expanded Bioprocess Design Centres will provide local expertise, advanced technologies and tailored support for biopharma innovators throughout the region

EIB and Angelini Ventures launch €150m fund to boost European biotech, medtech and digital health startups

The EIB and Angelini Ventures will co-invest €150 million to scale innovative European healthtech companies. The deal marks the EIB’s first partnership with a corporate venture capital fund in the healthcare sector

Fresh capital flows into neurodegeneration, cancer and vascular-access developers

A string of funding rounds and strategic financing deals across Europe’s life-sciences sector is breathing new life into companies working on high-need treatments — from neurodegeneration to cancer and dialysis access

Budget 2025: EY comments on the industrial impact of the Autumn Budget

Mark Minihane, UK&I Industrials and Energy Tax Leader for EY, comments on the industrial implications of the Chancellor’s Autumn Budget

Response to Budget from the Institution of Chemical Engineers (IChemE)

On 26 November, the Chancellor of the Exchequer, the Rt Hon Rachel Reeves MP, delivered the 2025 UK Autumn Budget

Gates Foundation awards Keltic Pharma $1.3 million for malaria drug research

The University of Glasgow spin-out's malaria programme is moving towards IND enablement within the next 12 months and is designed to deliver a single-dose cure — a potential breakthrough in efforts to combat one of the world’s most lethal diseases
You need to be a subscriber to read this article.
Click here to find out more.

UK bioindustry edges toward a critical turning point after the autumn budget

New tax breaks promise to fuel UK biotech scale-ups, but escalating workspace rates threaten to slow the momentum

Aseptic spray drying: Transforming biotherapeutics for a new era

With interest in aseptic spray drying on the rise in the pharmaceutical industry, Dr Kevin Robinson spoke to GEA’s David Costes about how the company is combining process, engineering and technological expertise with market insights to provide a safe, reliable and high-performance technology for advanced biotherapeutic powder applications

Latest posts in Finance

You need to be a subscriber to read this article.
Click here to find out more.

Budget 2025: a missed opportunity for UK life sciences

Despite bold rhetoric, today’s Budget delivered little of the certainty, investment or strategic direction the UK life sciences sector urgently needs

Eli Lilly becomes first $1 trillion pharma company

Fuelled by the GLP-1 boom, the drugmaker's stock has surged by more than 35% this year, with the company reaching a $1 trillion valuation on Friday — becoming the first pharmaceutical company ever to achieve the milestone

HitGen secures Gates Foundation funding to advance drug discovery for tuberculosis, malaria and contraception

HitGen will use its DNA-encoded library platform to identify new drug leads for TB, malaria and non-hormonal contraception. The new Gates Foundation agreement expands on earlier collaboration to accelerate treatments for underserved diseases

hVIVO’s CRS secures more than £5m in early-phase clinical trial contracts to strengthen 2026 pipeline

hVIVO’s German subsidiary CRS has signed more than £5 million in early-phase clinical trial contracts across cardiometabolic, dermatology, infectious disease, renal and oncology, bolstering its 2026 orderbook and highlighting the growing cross-selling benefits across the Group

Sofinnova Partners closes €650m ($750m) Capital XI fund to boost early-stage biotech investment across Europe and the US

Sofinnova Partners has closed its flagship Capital XI fund at €650m, surpassing its target. The Paris-based firm will use the fund to advance early-stage biotech and medtech companies in Europe and North America

Johnson & Johnson to acquire Halda Therapeutics for $3.05bn, expanding US oncology drug pipeline

Johnson & Johnson has agreed to acquire Connecticut-based Halda Therapeutics for $3.05bn. The deal strengthens its oncology portfolio, including Halda’s first-in-class RIPTAC therapy for advanced prostate cancer

Pfizer completes $10bn acquisition of Metsera to kickstart its GLP-1 goals

The acquisition brings promising clinical-stage obesity candidates into Pfizer's portfolio, giving the pharma company a leg up in one of the most dynamic and high-growth therapeutic areas

Pfizer clinches $10bn deal to acquire weight-loss biotech Metsera after bidding war with Novo Nordisk

Metsera says that it has opted for Pfizer's revised deal after antitrust concerns surrounding rival Novo's bid for the biotech

Pfizer denied restraining order on rival Novo Nordisk in GLP-1 bidding war

The Delaware Chancery Judge rejected Pfizer's request for a temporary restraining order, arguing that the company's objections to Novo's proposed deal weren't a legitimate reason for stopping the competitor's offer

Custom Pharmaceuticals launches new company to foster breakthrough drug development and strategic partnerships

Custom Pharmaceuticals Ltd has launched Centrix Pharma Solutions, a new company dedicated to accelerating drug product development through collaboration with biotech firms and academic research

Metsera declares $10bn Novo deal "superior" after Pfizer files second lawsuit in GLP-1 row

Metsera has said Novo Nordisk’s revised offer is a “superior proposal” to Pfizer’s, escalating a high-stakes legal and acquisition battle and where Pfizer has filed a second lawsuit accusing Novo of anticompetitive behaviour and Metsera of collusion

Sponsor content

Almac announces multi-million-pound investment in Singapore

Almac Group has announced a multi-million-pound investment to expand its facility in Singapore, as the company marks ten years of operations in the country

CARBOGEN AMCIS secures refinancing to support growth and investment

CARBOGEN AMCIS today announced the successful refinancing and enhancement of its credit facilities through the banking syndication led by UBS Switzerland AG

Piramal Pharma reports Q2 and H1 FY26 results amid CDMO challenges

CDMO growth impacted by inventory destocking while consumer healthcare posts mid-teen growth

Gerresheimer adjusts 2025 guidance amid slower market growth

Transformation program launched to boost performance and free cash flow

GEA raises guidance following strong H1 performance

Revised forecast reflects improved margins, robust order intake and efficiency gains

Lonza delivers strong H1 2025 performance

Lonza delivers strong H1 2025 performance and upgrades 2025 full-year CDMO sales and margin outlook

Gerresheimer reports H1 2025 growth driven by Bormioli Pharma acquisition

Cosmetics and oral liquids markets dampen organic revenue but outlook remains strong

Almac completes a multi-million-pound investment enhancing cold chain capabilities in Craigavon

Almac Clinical Services, part of the Almac Group, has completed a multi-million-pound investment to enhance cold chain capabilities at its global headquarters in...

CARBOGEN AMCIS accelerates manufacturing capacity with CHF 25.5 million co-investment at Swiss sites

CARBOGEN AMCIS is pleased to announce a strategic co-investment of more than CHF 25 million with a long-standing Japanese customer to expand manufacturing capabilities at...

Gerresheimer adjusts guidance for Financial Year 2025

Gerresheimer is adjusting its guidance for 2025 due to continuing subdued demand in the cosmetics market and a decline in demand for plastic containment solutions for oral...

Almac Group hits record £1 billion revenue milestone

Strong financials support expansion in manufacturing and clinical capabilities

Lonza publishes updated 2024 financials ahead of One Lonza reporting

New CDMO platform structure supports upcoming half-year 2025 results